Companies /Healthcare
Zevra Therapeutics Inc
NASDAQ: ZVRA Biotechnology
$11.17
▲ $0.91 (+8.87%) today
Markets closed · 5:41am ET

Zevra Therapeutics (ZVRA) Q1 2025 Earnings

Reported May 13, 2025, 4:10pm ET · SEC source
$-0.06
Beat +66.92%
EPS · est. $-0.18
$20.4M
Beat +20.30%
Revenue · est. $17.0M
+9.5%
Beating market
ZVRA vs S&P since report
5 quarters
Consecutive EPS beats

How Did ZVRA Stock React to Q1 2025 Earnings?

% change · around the report
−3%0+3%+6%May 13May 14report 4:10pm ETearnings+0.1%+0.1%
−3%0+3%+6%May 13May 14earnings+0.1%+0.1%
ZVRA +0.1%S&P 500 +0.1%
−3%0+3%+6%May 13May 14report 4:10pm ETearnings+0.6%+0.1%
−3%0+3%+6%May 13May 14earnings+0.6%+0.1%
ZVRA +0.1%NASDAQ +0.6%
−5%0+5%+10%May 12May 21report 4:10pm ETearnings−0.6%+6.0%
−5%0+5%+10%May 12May 21earnings−0.6%+6.0%
ZVRA +6.0%S&P 500 −0.6%
−5%0+5%+10%May 12May 21report 4:10pm ETearnings−0.4%+6.0%
−5%0+5%+10%May 12May 21earnings−0.4%+6.0%
ZVRA +6.0%NASDAQ −0.4%
+3.43%
Day of report
+3.56%
Next session
+6.39%
One week
+12.10%
30 days

S&P 500 over the same 30 days: +2.57%.

Did ZVRA Beat Earnings? Q1 2025 Results

Yes. Zevra Therapeutics reported Q1 2025 earnings of $-0.06 a share on May 13, 2025, beating the $-0.18 consensus estimate by 66.9%. Revenue was $20.4M against a $17.0M estimate.

Zevra Therapeutics delivered a transformational first quarter in 2025, posting net revenue of $20.40 million against just $3.42 million in the year-ago period, as the commercial launch of MIPLYFFA, its FDA-approved therapy for Niemann-Pick disease type C, emerged as the defining driver of the company's financial inflection. The rare disease biotech reported a loss of $0.06 per share on a net loss of $3.10 million, a dramatic improvement from the $0.40 per share loss recorded in Q1 2024, with MIPLYFFA contributing $17.10 million in net product revenue alone. R&D expenses fell sharply to $3.26 million from $12.28 million a year earlier following completion of the KP1077 Phase 2 trial, helping offset rising SG&A costs tied to commercial infrastructure buildout. A post-quarter sale of a Priority Review Voucher for $150.00 million in gross proceeds lifted pro forma liquidity to approximately $217.00 million, giving management confidence to pursue a European Medicines Agency filing for MIPLYFFA in the second half of 2025 without near-term reliance on capital markets.

Key Takeaways
  • MIPLYFFA commercial launch driving significant revenue growth
  • Transition of all active U.S. EAP patients to commercial MIPLYFFA
  • R&D expense reduction of $9.0 million due to completion of KP1077 Phase 2 trial
  • Fair value adjustment related to warrant and CVR liability of $4.9 million benefiting other income

“We are continuing Zevra's transformation into a patient-centric, commercial-stage rare disease therapeutics company. With our bolstered cash balance, we are well-positioned to support our strategic priorities, including establishing MIPLYFFA® as the cornerstone of treatment for NPC globally, maximizing our commercial opportunity with OLPRUVA®, and supporting our growth through our development pipeline.”

Zevra Therapeutics CEO, on the earnings call

What Was Zevra Therapeutics's Outlook in Q1 2025?

Zevra expects to file the MIPLYFFA MAA with the European Medicines Agency in the second half of 2025. The company states that with pro forma cash, cash equivalents and investments of approximately $217 million (including net PRV proceeds received post-quarter), it has ample resources and financial flexibility to execute on its strategic priorities independent from the capital markets. Strategic priorities include establishing MIPLYFFA as the cornerstone of NPC treatment globally, maximizing OLPRUVA's commercial opportunity, and advancing the development pipeline including the Phase 3 DiSCOVER trial for celiprolol.

ZVRA YoY Financials

Revenue$20.4M
Operating Income$-5,362,000
Net Income$-3,099,000
Gross Profit$17.4M

ZVRA Revenue by Segment

MIPLYFFA$17.1M
Expanded Access Program
French EAP Arimoclomol Reimbursements
French EAP for arimoclomol$2.3M
AZSTARYS License Agreement
AZSTARYS Royalties and Reimbursements
AZSTARYS royalties and reimbursements$900,000
OLPRUVA$100,000

Figures from SEC filings and company reports. Not investment advice.